A
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Gastrointestinal Cancers
- Tumour Sub-type
- Pancreatic cancer
- Tumour stage
- Early
- Control Arm
- Gemcitabine
- Treatment Setting
- Resected pancreatic ductal adenocarcinoma
- Trial Name
- PRODIGE 24/CCTG PA. 6 trial
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Form(s)
- Form 1
Outcome Data
- OS Control
- 35.0 months
- OS Gain
- 19.4 months 3-year survival gain 14.8%
- OS HR
- 0.64 (0.48-0.86)
- Toxicity Comment
- Increased acute toxicity
Final Score (after adjustments)
- Final curative score
- A
- Release date
- 14.05.2019